Back to the main directory
EarningsReview / Equity
- Alligator Bioscience (Buy, TP: SEK1.50) - Rights issue announced by DnB Markets
- More attractive risk/reward post-Q4 by DnB Markets
- Vaisala Oyj - Strong orders turn mixed Q4 result into a positive by Danske Bank Equity Research
- Middle East: 10% of the rooms, 20% of the plan by BNP Paribas Exane
- Castellum - Buy/SEK 145: In a good position to offset market softness by Nordea
- Solid guide for ’24, record XScale bookings and positive cab adds by BNP Paribas Exane
- Q1 the trough with q/q growth through 2024 by BNP Paribas Exane
- Kempower Oyj - Buy/EUR 28.20 (36.90): Reset of market expectations by Nordea
- Terveystalo - Buy/EUR 9.50: Positive trajectory going into 2024 by Nordea
- Mapfre - New plan in March: we expect 9-10% RoE target for 2024-26; Buy by JB Capital Markets
- 2024 guidance reiterated, growth notable above peer set by BNP Paribas Exane
- Finnair - Buy/EUR 0.05 (Hold): Capacity growth could surpass 10% in 2024 by Nordea
- Norsk Hydro - Hold: Continued soft outlook by Nordea
- It’s bean even more inflationary by BNP Paribas Exane
- Guidance reaffirmed, solid activity with equity raise in rear view by BNP Paribas Exane
- Scandic Hotels - Buy/SEK 75 (76): Positive capex guidance by Nordea
- To: 2024, Cc: Credit and Capital by BNP Paribas Exane
- ‘24 guidance modestly below, but growth CAGR still appealing by BNP Paribas Exane
- Mowi - A low capex level is only short term by Danske Bank Equity Research
- Aedas Homes - Soft 3Q23 but on track to meet FY23 guidance; Buy by JB Capital Markets
- Seeking the right balance by BNP Paribas Exane
- Rollins Q4 - Read-X to Rentokil by BNP Paribas Exane
- AEDAS: RDOS. 9MESES’23 (ANÁLISIS BANCO SABADELL) by Sabadell
- INVEST SECURITIES – CARMILA :Un engagement fort sur la distribution conforté par des perspectives bien orientées - ACHAT, OC 19,0€ vs 18,2€ by Invest Securities
- Svas Biosana S.p.A. - Croissance et Vision by MidCap Partners